NASDAQ:OXFD - Oxford Immunotec Global Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$13.51 +0.01 (+0.07 %)
(As of 05/21/2018 06:00 AM ET)
Previous Close$13.51
Today's Range$13.49 - $13.70
52-Week Range$10.00 - $19.51
Volume72,096 shs
Average Volume87,285 shs
Market Capitalization$349.65 million
P/E Ratio-9.93
Dividend YieldN/A
Beta-0.33

About Oxford Immunotec Global (NASDAQ:OXFD)

Oxford Immunotec Global logoOxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology. The company develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. It develops and markets T-SPOT.TB test used to test for tuberculosis. The company is also developing a range of assays for tick-borne diseases, such as lyme disease, as well as for use in screening blood for the parasite babesia microti that causes babesiosis; and T-SPOT.CMV test that measures the strength of a patient's cellular response to CMV infection. Oxford Immunotec Global PLC markets its T-SPOT.TB test through a direct sales force in the United States, certain European countries, and Japan, as well as through distributors in other parts of the world. Oxford Immunotec Global PLC was founded in 2002 and is headquartered in Abingdon, the United Kingdom.

Receive OXFD News and Ratings via Email

Sign-up to receive the latest news and ratings for OXFD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OXFD
CUSIPN/A
Phone44-0-12-3544-2780

Debt

Debt-to-Equity Ratio0.38
Current Ratio5.60
Quick Ratio5.04

Price-To-Earnings

Trailing P/E Ratio-9.93
Forward P/E Ratio-13.79
P/E GrowthN/A

Sales & Book Value

Annual Sales$103.08 million
Price / Sales3.39
Cash FlowN/A
Price / CashN/A
Book Value$3.08 per share
Price / Book4.39

Profitability

EPS (Most Recent Fiscal Year)($1.36)
Net Income$-32,880,000.00
Net Margins-34.13%
Return on Equity-43.51%
Return on Assets-24.49%

Miscellaneous

Employees457
Outstanding Shares25,880,000

Oxford Immunotec Global (NASDAQ:OXFD) Frequently Asked Questions

What is Oxford Immunotec Global's stock symbol?

Oxford Immunotec Global trades on the NASDAQ under the ticker symbol "OXFD."

How were Oxford Immunotec Global's earnings last quarter?

Oxford Immunotec Global PLC (NASDAQ:OXFD) issued its quarterly earnings results on Tuesday, May, 1st. The company reported ($0.40) EPS for the quarter, topping the Zacks' consensus estimate of ($0.45) by $0.05. The firm had revenue of $21.37 million for the quarter, compared to analyst estimates of $20.96 million. Oxford Immunotec Global had a negative net margin of 34.13% and a negative return on equity of 43.51%. The business's revenue for the quarter was down .7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.36) EPS. View Oxford Immunotec Global's Earnings History.

When is Oxford Immunotec Global's next earnings date?

Oxford Immunotec Global is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Oxford Immunotec Global.

What price target have analysts set for OXFD?

4 analysts have issued 1-year price targets for Oxford Immunotec Global's stock. Their forecasts range from $15.00 to $20.00. On average, they expect Oxford Immunotec Global's share price to reach $18.25 in the next year. View Analyst Ratings for Oxford Immunotec Global.

Who are some of Oxford Immunotec Global's key competitors?

Who are Oxford Immunotec Global's key executives?

Oxford Immunotec Global's management team includes the folowing people:
  • Dr. Peter Wrighton-Smith, CEO & Exec. Director (Age 44)
  • Mr. Richard M. Altieri, CFO and Principal Financial & Accounting Officer (Age 58)
  • Mr. Jeff R. Schroeder, Pres, Strategic Accounts (Age 57)
  • Mr. Stefan C. Linn, Chief Operating Officer (Age 53)
  • Ms. Karen C. Koski, Head of Strategy & Investor Relations

Has Oxford Immunotec Global been receiving favorable news coverage?

News articles about OXFD stock have been trending somewhat positive recently, Accern reports. The research group scores the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Oxford Immunotec Global earned a coverage optimism score of 0.13 on Accern's scale. They also gave news headlines about the company an impact score of 47.30 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Who are Oxford Immunotec Global's major shareholders?

Oxford Immunotec Global's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Redmile Group LLC (9.54%), BlackRock Inc. (4.49%), Wasatch Advisors Inc. (2.88%), First Light Asset Management LLC (2.42%), Cortina Asset Management LLC (1.98%) and Northern Trust Corp (1.00%). Company insiders that own Oxford Immunotec Global stock include Elizabeth M Keiley, Jeff R Schroeder, Peter Edwardson, Peter Wrighton-Smith and Richard A Sandberg. View Institutional Ownership Trends for Oxford Immunotec Global.

Which major investors are selling Oxford Immunotec Global stock?

OXFD stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Cortina Asset Management LLC, Tiverton Asset Management LLC, Millennium Management LLC, Neuburgh Advisers LLC, Flinton Capital Management LLC, C WorldWide Group Holding A S and Northern Trust Corp. Company insiders that have sold Oxford Immunotec Global company stock in the last year include Elizabeth M Keiley, Peter Edwardson, Peter Wrighton-Smith and Richard A Sandberg. View Insider Buying and Selling for Oxford Immunotec Global.

Which major investors are buying Oxford Immunotec Global stock?

OXFD stock was acquired by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Redmile Group LLC, BlackRock Inc., Spark Investment Management LLC, Birchview Capital LP, First Light Asset Management LLC, Trexquant Investment LP and Kornitzer Capital Management Inc. KS. View Insider Buying and Selling for Oxford Immunotec Global.

How do I buy shares of Oxford Immunotec Global?

Shares of OXFD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Oxford Immunotec Global's stock price today?

One share of OXFD stock can currently be purchased for approximately $13.51.

How big of a company is Oxford Immunotec Global?

Oxford Immunotec Global has a market capitalization of $349.65 million and generates $103.08 million in revenue each year. The company earns $-32,880,000.00 in net income (profit) each year or ($1.36) on an earnings per share basis. Oxford Immunotec Global employs 457 workers across the globe.

How can I contact Oxford Immunotec Global?

Oxford Immunotec Global's mailing address is 94C INNOVATION DRIVE MILTON PARK, ABINGDON X0, OX14 4RZ. The company can be reached via phone at 44-0-12-3544-2780 or via email at [email protected]


MarketBeat Community Rating for Oxford Immunotec Global (OXFD)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  141 (Vote Outperform)
Underperform Votes:  120 (Vote Underperform)
Total Votes:  261
MarketBeat's community ratings are surveys of what our community members think about Oxford Immunotec Global and other stocks. Vote "Outperform" if you believe OXFD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OXFD will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Oxford Immunotec Global (NASDAQ:OXFD) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Oxford Immunotec Global in the last 12 months. Their average twelve-month price target is $18.25, suggesting that the stock has a possible upside of 35.09%. The high price target for OXFD is $20.00 and the low price target for OXFD is $15.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $18.25$18.75$18.75$19.75
Price Target Upside: 35.09% upside62.90% upside62.90% upside49.39% upside

Oxford Immunotec Global (NASDAQ:OXFD) Consensus Price Target History

Price Target History for Oxford Immunotec Global (NASDAQ:OXFD)

Oxford Immunotec Global (NASDAQ:OXFD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/1/2018BTIG ResearchSet Price TargetBuy$19.00MediumView Rating Details
1/22/2018CowenReiterated RatingBuy$15.00HighView Rating Details
11/1/2017Robert W. BairdReiterated RatingBuy$20.00N/AView Rating Details
10/31/2017Piper Jaffray CompaniesLower Price TargetOverweight$26.00 ➝ $19.00N/AView Rating Details
(Data available from 5/21/2016 forward)

Earnings

Oxford Immunotec Global (NASDAQ:OXFD) Earnings History and Estimates Chart

Earnings by Quarter for Oxford Immunotec Global (NASDAQ:OXFD)

Oxford Immunotec Global (NASDAQ:OXFD) Earnings Estimates

2018 EPS Consensus Estimate: ($1.05)
2019 EPS Consensus Estimate: ($0.79)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.46)($0.46)($0.46)
Q2 20181($0.22)($0.22)($0.22)
Q3 20181($0.12)($0.12)($0.12)
Q4 20181($0.25)($0.25)($0.25)
Q1 20191($0.36)($0.36)($0.36)
Q2 20191($0.19)($0.19)($0.19)
Q3 20191($0.05)($0.05)($0.05)
Q4 20191($0.19)($0.19)($0.19)

Oxford Immunotec Global (NASDAQ OXFD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2018        
5/1/2018Q1 2018($0.45)($0.40)$20.96 million$21.37 millionViewListenView Earnings Details
2/27/2018Q4 2017($0.36)($0.34)$25.12 million$25.03 millionViewN/AView Earnings Details
10/31/2017Q3 2017($0.26)($0.24)$30.11 million$30.43 millionViewN/AView Earnings Details
8/1/2017Q2 2017($0.32)($0.32)$25.05 million$26.10 millionViewListenView Earnings Details
5/2/20173/31/2017($0.35)($0.36)$21.17 million$21.51 millionViewListenView Earnings Details
3/1/201712/31/2016($0.39)($0.22)$23.06 million$23.71 millionViewListenView Earnings Details
11/1/2016Q316($0.33)($0.18)$24.79 million$26.10 millionViewN/AView Earnings Details
8/2/2016Q216($0.33)($0.29)$18.10 million$19.20 millionViewN/AView Earnings Details
5/3/2016Q116($0.32)($0.32)$16.96 million$17.10 millionViewN/AView Earnings Details
3/1/2016Q415($0.28)($0.29)$16.34 million$16.00 millionViewN/AView Earnings Details
11/3/2015Q315($0.25)($0.20)$17.31 million$17.90 millionViewN/AView Earnings Details
8/4/2015Q215($0.34)($0.33)$14.04 million$14.30 millionViewN/AView Earnings Details
5/5/2015Q115($0.33)($0.31)$13.35 million$13.80 millionViewN/AView Earnings Details
3/3/2015Q414($0.44)($0.39)$11.93 million$12.10 millionViewN/AView Earnings Details
11/4/2014Q314($0.38)($0.35)$12.85 million$13.30 millionViewN/AView Earnings Details
8/5/2014Q214($0.20)($0.36)$11.39 million$11.80 millionViewN/AView Earnings Details
5/6/2014Q114($0.18)($0.18)$11.64 million$12.30 millionViewN/AView Earnings Details
3/4/2014Q413($0.19)($0.38)$9.28 million$10.20 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Oxford Immunotec Global (NASDAQ:OXFD) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Oxford Immunotec Global (NASDAQ OXFD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.11%
Institutional Ownership Percentage: 93.22%
Insider Trading History for Oxford Immunotec Global (NASDAQ:OXFD)
Institutional Ownership by Quarter for Oxford Immunotec Global (NASDAQ:OXFD)

Oxford Immunotec Global (NASDAQ OXFD) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/1/2018Richard A SandbergDirectorSell3,000$12.77$38,310.0018,000View SEC Filing  
2/16/2018Richard A SandbergDirectorSell3,000$12.01$36,030.00View SEC Filing  
11/1/2017Richard A SandbergDirectorSell3,000$13.35$40,050.0017,778View SEC Filing  
10/2/2017Peter Wrighton-SmithCEOSell55,000$16.78$922,900.00View SEC Filing  
9/1/2017Richard A SandbergDirectorSell3,000$15.82$47,460.0018,000View SEC Filing  
8/15/2017Peter EdwardsonCOOSell9,739$16.14$157,187.4692,905View SEC Filing  
8/7/2017Peter EdwardsonCOOSell22,371$17.70$395,966.70102,644View SEC Filing  
7/6/2017Peter Wrighton-SmithCEOSell27,168$15.94$433,057.92488,836View SEC Filing  
7/5/2017Peter Wrighton-SmithCEOSell32,832$16.58$544,354.56478,106View SEC Filing  
6/28/2017Peter Wrighton-SmithCEOSell30,000$16.06$481,800.00491,668View SEC Filing  
6/15/2017Elizabeth M KeileyVPSell4,085$15.01$61,315.8525,393View SEC Filing  
5/15/2017Peter EdwardsonCOOSell10,000$14.66$146,600.00125,015View SEC Filing  
5/10/2017Richard A SandbergDirectorSell3,000$14.40$43,200.0020,174View SEC Filing  
5/9/2017Jeff R SchroederInsiderSell40,000$14.14$565,600.00149,544View SEC Filing  
4/3/2017Peter Wrighton-SmithCEOSell30,000$15.43$462,900.00491,668View SEC Filing  
4/3/2017Richard A SandbergDirectorSell3,000$15.47$46,410.0017,174View SEC Filing  
3/20/2017Elizabeth M KeileyVPSell3,000$16.05$48,150.0025,429View SEC Filing  
2/6/2017Peter Wrighton-SmithCEOSell25,000$13.36$334,000.00463,495View SEC Filing  
12/16/2016Peter Wrighton-SmithCEOSell7,052$15.07$106,273.64450,366View SEC Filing  
12/5/2016Peter Wrighton-SmithCEOSell1,140$15.00$17,100.00444,454View SEC Filing  
12/2/2016Peter Wrighton-SmithCEOSell61,808$15.00$927,120.00504,122View SEC Filing  
11/8/2016Richard A SandbergDirectorSell12,000$14.17$170,040.0031,774View SEC Filing  
11/18/2015Richard A. SandbergDirectorSell5,000$13.48$67,400.0032,174View SEC Filing  
11/17/2015Richard A. SandbergDirectorSell5,000$13.00$65,000.0037,174View SEC Filing  
6/16/2015Lifesciences I L.P. ClarusMajor ShareholderSell41,230$14.30$589,589.00View SEC Filing  
6/15/2015Lifesciences I L.P. ClarusMajor ShareholderSell1,529$14.27$21,818.83View SEC Filing  
6/12/2015Lifesciences I L.P. ClarusMajor ShareholderSell31,598$14.27$450,903.46View SEC Filing  
6/10/2015Lifesciences I L.P. ClarusMajor ShareholderSell24,649$14.28$351,987.72View SEC Filing  
6/9/2015Lifesciences I L.P. ClarusMajor ShareholderSell13,000$14.26$185,380.00View SEC Filing  
6/8/2015Lifesciences I L.P. ClarusMajor ShareholderSell2,662$14.25$37,933.50View SEC Filing  
6/3/2015Lifesciences I L.P. ClarusMajor ShareholderSell36,474$14.29$521,213.46View SEC Filing  
6/1/2015Richard A SandbergDirectorSell3,000$14.14$42,420.00View SEC Filing  
3/23/2015Lifesciences I L.P. ClarusMajor ShareholderSell53,415$14.49$773,983.35View SEC Filing  
3/19/2015Lifesciences I L.P. ClarusMajor ShareholderSell154,319$14.65$2,260,773.35View SEC Filing  
1/14/2015Richard A SandbergDirectorSell3,000$14.00$42,000.00View SEC Filing  
12/5/2014Patricia RandallDirectorSell5,000$12.06$60,300.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Oxford Immunotec Global (NASDAQ OXFD) News Headlines

Source:
DateHeadline
 Brokerages Anticipate Oxford Immunotec Global PLC (OXFD) to Announce -$0.24 Earnings Per Share Brokerages Anticipate Oxford Immunotec Global PLC (OXFD) to Announce -$0.24 Earnings Per Share
www.americanbankingnews.com - May 20 at 7:22 PM
Oxford Immunotec to Present at the 2018 UBS Global Healthcare ConferenceOxford Immunotec to Present at the 2018 UBS Global Healthcare Conference
finance.yahoo.com - May 16 at 9:46 AM
Oxford Immunotec Global (OXFD) Downgraded by BidaskClubOxford Immunotec Global (OXFD) Downgraded by BidaskClub
www.americanbankingnews.com - May 11 at 7:53 PM
Oxford Immunotec Global (OXFD) Lifted to Buy at BidaskClubOxford Immunotec Global (OXFD) Lifted to Buy at BidaskClub
www.americanbankingnews.com - May 5 at 6:37 AM
 Analysts Anticipate Oxford Immunotec Global (OXFD) Will Announce Quarterly Sales of $28.55 Million Analysts Anticipate Oxford Immunotec Global (OXFD) Will Announce Quarterly Sales of $28.55 Million
www.americanbankingnews.com - May 5 at 4:01 AM
Oxford Immunotec Global (OXFD) Receives Consensus Rating of "Hold" from BrokeragesOxford Immunotec Global (OXFD) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - May 5 at 1:48 AM
 Brokerages Anticipate Oxford Immunotec Global (OXFD) to Post -$0.23 EPS Brokerages Anticipate Oxford Immunotec Global (OXFD) to Post -$0.23 EPS
www.americanbankingnews.com - May 3 at 2:57 PM
Piper Jaffray Weighs in on Oxford Immunotec Globals Q2 2018 Earnings (OXFD)Piper Jaffray Weighs in on Oxford Immunotec Global's Q2 2018 Earnings (OXFD)
www.americanbankingnews.com - May 3 at 8:06 AM
Oxford Immunotec Global (OXFD) Rating Increased to Hold at ValuEngineOxford Immunotec Global (OXFD) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - May 2 at 10:58 PM
Oxford Immunotec Global (OXFD) Director Sells $38,310.00 in StockOxford Immunotec Global (OXFD) Director Sells $38,310.00 in Stock
www.americanbankingnews.com - May 2 at 8:16 PM
Oxford Immunotec Global (OXFD) Stock Rating Lowered by Zacks Investment ResearchOxford Immunotec Global (OXFD) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - May 2 at 12:52 PM
BTIG Research Reiterates $19.00 Price Target for Oxford Immunotec Global (OXFD)BTIG Research Reiterates $19.00 Price Target for Oxford Immunotec Global (OXFD)
www.americanbankingnews.com - May 2 at 12:08 PM
Edited Transcript of OXFD earnings conference call or presentation 1-May-18 12:00pm GMTEdited Transcript of OXFD earnings conference call or presentation 1-May-18 12:00pm GMT
finance.yahoo.com - May 2 at 9:27 AM
Oxford Immunotec Globals (OXFD) CEO Peter Wrighton-Smith on Q1 2018 Results - Earnings Call TranscriptOxford Immunotec Global's (OXFD) CEO Peter Wrighton-Smith on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 1 at 4:22 PM
Oxford Immunotec: 1Q Earnings SnapshotOxford Immunotec: 1Q Earnings Snapshot
finance.yahoo.com - May 1 at 4:22 PM
Oxford Immunotec Global (OXFD) Issues Quarterly  Earnings ResultsOxford Immunotec Global (OXFD) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 1 at 9:50 AM
Oxford Immunotec Reports First Quarter 2018 Financial ResultsOxford Immunotec Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 1 at 9:31 AM
Oxford Immunotec Global (OXFD) Set to Announce Quarterly Earnings on TuesdayOxford Immunotec Global (OXFD) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - April 24 at 10:56 AM
BidaskClub Downgrades Oxford Immunotec Global (OXFD) to HoldBidaskClub Downgrades Oxford Immunotec Global (OXFD) to Hold
www.americanbankingnews.com - April 24 at 9:58 AM
Oxford Immunotec Global (OXFD) Lowered to Hold at Zacks Investment ResearchOxford Immunotec Global (OXFD) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - April 24 at 8:58 AM
Oxford Immunotec Global (OXFD) and Its Peers Financial SurveyOxford Immunotec Global (OXFD) and Its Peers Financial Survey
www.americanbankingnews.com - April 19 at 5:23 PM
Q1 2018 EPS Estimates for Oxford Immunotec Global Lowered by Analyst (OXFD)Q1 2018 EPS Estimates for Oxford Immunotec Global Lowered by Analyst (OXFD)
www.americanbankingnews.com - April 19 at 6:50 AM
Oxford Immunotec Global (OXFD) Expected to Announce Quarterly Sales of $20.91 MillionOxford Immunotec Global (OXFD) Expected to Announce Quarterly Sales of $20.91 Million
www.americanbankingnews.com - April 18 at 4:16 AM
Oxford Immunotec Schedules First Quarter 2018 Earnings Release and Conference Call for May 1, 2018Oxford Immunotec Schedules First Quarter 2018 Earnings Release and Conference Call for May 1, 2018
finance.yahoo.com - April 17 at 9:51 AM
-$0.40 EPS Expected for Oxford Immunotec Global (OXFD) This Quarter-$0.40 EPS Expected for Oxford Immunotec Global (OXFD) This Quarter
www.americanbankingnews.com - April 16 at 7:13 AM
Oxford Immunotec Global (OXFD) & Its Peers Head-To-Head ComparisonOxford Immunotec Global (OXFD) & Its Peers Head-To-Head Comparison
www.americanbankingnews.com - April 14 at 7:21 PM
Oxford Immunotec Global (OXFD) Earns Buy Rating from Piper JaffrayOxford Immunotec Global (OXFD) Earns Buy Rating from Piper Jaffray
www.americanbankingnews.com - April 13 at 6:01 PM
Oxford Immunotec Global (OXFD) Earns Buy Rating from CowenOxford Immunotec Global (OXFD) Earns Buy Rating from Cowen
www.americanbankingnews.com - April 13 at 6:01 PM
Head to Head Analysis: Oxford Immunotec Global (OXFD) vs. Its CompetitorsHead to Head Analysis: Oxford Immunotec Global (OXFD) vs. Its Competitors
www.americanbankingnews.com - April 11 at 8:47 AM
Critical Contrast: Oxford Immunotec Global (OXFD) versus Its CompetitorsCritical Contrast: Oxford Immunotec Global (OXFD) versus Its Competitors
www.americanbankingnews.com - April 10 at 9:15 AM
Oxford Immunotec Global (OXFD) Receives Consensus Recommendation of "Buy" from AnalystsOxford Immunotec Global (OXFD) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 10 at 1:41 AM
Trinity Biotech (TRIB) versus Oxford Immunotec Global (OXFD) Financial ReviewTrinity Biotech (TRIB) versus Oxford Immunotec Global (OXFD) Financial Review
www.americanbankingnews.com - April 8 at 9:19 PM
Head to Head Comparison: Oxford Immunotec Global (OXFD) vs. Its RivalsHead to Head Comparison: Oxford Immunotec Global (OXFD) vs. Its Rivals
www.americanbankingnews.com - April 7 at 11:15 PM
Oxford Immunotec Global (OXFD) Rating Reiterated by Robert W. BairdOxford Immunotec Global (OXFD) Rating Reiterated by Robert W. Baird
www.americanbankingnews.com - April 2 at 1:30 PM
Vermillion (VRML) & Oxford Immunotec Global (OXFD) Head to Head ComparisonVermillion (VRML) & Oxford Immunotec Global (OXFD) Head to Head Comparison
www.americanbankingnews.com - April 2 at 3:06 AM
Oxford Immunotec Global (OXFD) Expected to Post Quarterly Sales of $21.69 MillionOxford Immunotec Global (OXFD) Expected to Post Quarterly Sales of $21.69 Million
www.americanbankingnews.com - April 1 at 4:20 AM
Zacks: Analysts Expect Oxford Immunotec Global (OXFD) Will Announce Earnings of -$0.38 Per ShareZacks: Analysts Expect Oxford Immunotec Global (OXFD) Will Announce Earnings of -$0.38 Per Share
www.americanbankingnews.com - March 30 at 10:02 AM
Oxford Immunotec Global (OXFD) Downgraded to Sell at BidaskClubOxford Immunotec Global (OXFD) Downgraded to Sell at BidaskClub
www.americanbankingnews.com - March 28 at 9:16 PM
Oxford Immunotec Globals (OXFD) Buy Rating Reaffirmed at CowenOxford Immunotec Global's (OXFD) Buy Rating Reaffirmed at Cowen
www.americanbankingnews.com - March 27 at 12:40 AM
Oxford Immunotec Global (OXFD) Upgraded at Zacks Investment ResearchOxford Immunotec Global (OXFD) Upgraded at Zacks Investment Research
www.americanbankingnews.com - March 26 at 9:18 PM
Reviewing Oxford Immunotec Global (OXFD) and Its PeersReviewing Oxford Immunotec Global (OXFD) and Its Peers
www.americanbankingnews.com - March 23 at 12:48 PM
Oxford Immunotec Global PLC (OXFD) Given Average Recommendation of "Buy" by AnalystsOxford Immunotec Global PLC (OXFD) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - March 16 at 1:54 AM
Oxford Immunotec Global PLC (OXFD) Expected to Announce Quarterly Sales of $21.69 MillionOxford Immunotec Global PLC (OXFD) Expected to Announce Quarterly Sales of $21.69 Million
www.americanbankingnews.com - March 15 at 2:58 PM
Oxford Immunotec Global (OXFD) Upgraded at BidaskClubOxford Immunotec Global (OXFD) Upgraded at BidaskClub
www.americanbankingnews.com - March 14 at 7:12 PM
ValuEngine Upgrades Oxford Immunotec Global (OXFD) to "Sell"ValuEngine Upgrades Oxford Immunotec Global (OXFD) to "Sell"
www.americanbankingnews.com - March 11 at 11:13 PM
Zacks Investment Research Upgrades Oxford Immunotec Global (OXFD) to "Buy"Zacks Investment Research Upgrades Oxford Immunotec Global (OXFD) to "Buy"
www.americanbankingnews.com - March 10 at 4:24 PM
Oxford Immunotec to Present at Two Upcoming Investor ConferencesOxford Immunotec to Present at Two Upcoming Investor Conferences
finance.yahoo.com - March 6 at 9:22 AM
Oxford Immunotec Global (OXFD) Downgraded to Strong Sell at ValuEngineOxford Immunotec Global (OXFD) Downgraded to Strong Sell at ValuEngine
www.americanbankingnews.com - March 4 at 1:02 PM
Oxford Immunotec Global PLC 2017 Q4 - Results - Earnings Call SlidesOxford Immunotec Global PLC 2017 Q4 - Results - Earnings Call Slides
seekingalpha.com - February 28 at 9:27 AM
Oxford Immunotec Global (OXFD) Releases  Earnings Results, Beats Expectations By $0.03 EPSOxford Immunotec Global (OXFD) Releases Earnings Results, Beats Expectations By $0.03 EPS
www.americanbankingnews.com - February 27 at 5:32 PM

SEC Filings

Oxford Immunotec Global (NASDAQ:OXFD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Oxford Immunotec Global (NASDAQ:OXFD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Oxford Immunotec Global (NASDAQ OXFD) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.